Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
Beijing eases restrictions on home
King Charles returns to public duties after cancer diagnosis
Biden administration details how producers of sustainable aviation fuel will get tax credits
US overdose deaths dropped in 2023, the first time since 2018
Why Mean Girls' most iconic lines are still used today
Trump's comparison of student protests to Jan. 6 is part of effort to downplay Capitol attack
King Charles returns to public duties after cancer diagnosis
Xander Schauffele gets validation and records with one memorable putt at PGA Championship
Harvey Weinstein's $300million net worth plummets to $25million since his 2017 downfall
Key evidence in the 'burking' murder trial was 'hidden' from defence lawyers
Biden administration details how producers of sustainable aviation fuel will get tax credits